Journal article

Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis

Julia ML Brotherton, Alison Budd, Christopher Rompotis, Natasha Bartlett, Michael J Malloy, Rachael L Andersen, Kim AR Coulter, Peter W Couvee, Nerida Steel, Gail H Ward, Marion Saville

Papillomavirus Research | ELSEVIER | Published : 2019

Abstract

AIM: Prophylactic human papillomavirus (HPV) vaccines are highly effective at preventing pre-cancerous cervical lesions when given in a three-dose schedule. Some post-hoc trial data suggest that one dose prevents HPV infection. If one dose could prevent pre-cancerous cervical lesions, then global cervical cancer prevention would be greatly facilitated. We assessed the effectiveness of quadrivalent HPV vaccine by number of doses against cervical intraepithelial neoplasia (CIN) 2 or 3/adenocarcinoma-in-situ (AIS)/cancer in Australia up to seven years post vaccination. METHODS: We linked registry data from all 8 jurisdictional cervical screening registers, with the national HPV vaccination regi..

View full abstract

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

The data linkage and analysis of this study were funded by the Australian Department of Health. The funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. JMLB, AB and MS are investigators in the National Health and Medical Research Council funded Centre for Research Excellence in Cervical Cancer Control (APP1135172).